[Seungkwon kim, Edaily Reporter]SK Biopharm announced Wednesday that it will participate in the 2025 BIO International Convention (BIO USA), held in Boston from June 16 to 19, marking the first time the company will host an independent booth at the event.

BIO USA, organized by the Biotechnology Innovation Organization (BIO), is the world’s largest biotechnology exhibition. It brings together over 20,000 industry professionals from more than 65 countries to explore promising technologies and business collaborations.

SK Biopharm

Through its solo booth, SK Biopharm aims to enhance its brand presence and credibility while actively seeking new global partnerships through one-on-one business meetings and interactive displays. The booth features the company’s signature orange as an accent color and a design that incorporates soft curves for high visibility and accessibility from all directions, reflecting a user-friendly and approachable concept.

Under the slogan “SK, For Patients, For Life,” the company plans to highlight its core value of patient-centered care and its commitment to sustainable innovation. A major focus will be on Cenobamate (U.S. brand name: XCOPRI®), its innovative anti-seizure medication developed in-house, which has gained significant traction in the U.S. market.

Since its launch in 2020, Cenobamate has been rapidly adopted, with more than 170,000 cumulative patients prescribed as of the first half of 2025. SK Biopharm attributes the drug’s continued growth to a nationwide direct-to-consumer (DTC) campaign that has boosted brand awareness and improved access to treatment. The company will showcase the campaign videos and real patient testimonials at the booth to strengthen its global positioning.

“BIO USA is a critical opportunity for us to share SK Biopharm’s vision and accomplishments on the global stage,” said Donghoon Lee, CEO of SK Biopharm. “We remain committed to patient-centered innovation and will continue to expand treatment solutions that improve the lives of patients worldwide.”